Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

4.700 +0.520 (+12.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Diamedica Therapeutics Inc

< Previous 1 2 3 4 5 Next >
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: DiaMedica Therapeutics's Earnings
Via Benzinga
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Recap: DiaMedica Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For DiaMedica Therapeutics
Via Benzinga
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
DiaMedica Therapeutics Upcoming Conference Participation
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback